glp 1 mechanism of action ppt Semaglutide Advances In Receptor Agonist Therapy Demonstration AT glp 1 mechanism of action

Specifically, 2-OG has been shown to be an agonist of GPR119, a receptor that plays a key role in promoting GLP-1 release in humans

Obesity is now thought of as a chronic condition, much like diabetes or hypertension

Beyond weight and blood sugar, studies like the SELECT trial have shown that GLP-1s also reduce the risk of heart attacks and strokes

In January 2026, Novo Nordisk, the makers of Ozempic (semaglutide), released the drug as daily oral pill

Tirzepatide produces greater weight loss and may have stronger effects on insulin sensitivity

Suppose, instead, that the microbes used for production were also edible